Zydus Cadila says its ZyCoV-D vaccine had very good results in Phase 1 and 2 trials. Dosing of participants in Phase 3 has been completed and the data analysis process is underway. However, not a single vaccine using its unique platform has been approved anywhere in the world. ZyCoV-D is also a three-dose vaccine, which could post logistical and administration challenges and weigh on pricing.How to protect and exponentially Grow your investment portfolio during economic boom or bust, How learn stock market, How to earn money in stock market,earn money from home .
Zydus Cadilaâs Covid-19 vaccine: How it compares with peers, manufacturing capacities and challenges, explained
Zydus Cadila says its ZyCoV-D vaccine had very good results in Phase 1 and 2 trials. Dosing of participants in Phase 3 has been completed and the data analysis process is underway. However, not a single vaccine using its unique platform has been approved anywhere in the world. ZyCoV-D is also a three-dose vaccine, which could post logistical and administration challenges and weigh on pricing.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment